1. paclitaxel 135 mg m -2 by 24-h intravenous (iv.) infusion + cisplatin 75 mg m -2 2. paclitaxel 250 mg m -2 by 24-h i.v. infusion + cisplatin also at 75 mg m -2 + G-CSF 3. standard etoposide 100 mg m -2 i.v. × 3 days + cisplatin 75 mg m -2 .
The response rates were found to be higher with the paclitaxelcontaining regimens: 26% in the paclitaxel/cisplatin group and 31% in the paclitaxel/cisplatin/G-CSF group, versus 12% for the etoposide/cisplatin group. The two paclitaxel-containing arms had almost identical survival and were grouped together for survival analysis. This revealed a statistically significant improvement in the median survival, 9.7 months in the combined paclitaxel arms compared with 7.4 months for etoposide/cisplatin (log-rank P = 0.049). Additionally, 39% of patients treated with paclitaxel/cisplatin and 40% of those treated with paclitaxel/ cisplatin/G-CSF were alive at 1 year, compared to 32% of those receiving etoposide/cisplatin. However, this was not statistically significant.
Five of seven quality of life indices assessed during the trial did not differ among the three treatment arms. The remaining two domains favoured those treated with paclitaxel-containing regimens: lung cancer symptoms were significantly better in the paclitaxel-treated patients (P = 0.027) and there was a trend towards improved emotional well-being (P = 0.079).
Determination of treatment costs
In order to assess treatment costs, we obtained resource utilization data from the ECOG randomized trial. To ascertain the total direct cost to the Canadian health care system for these treatments, we had to make a number of assumptions. We determined the average doses and number of treatment cycles from the pooled drug administration records of patients in the trial and assumed that each patient in our analysis received this same treatment. We assumed that the 24-h infusions required 1 day of hospitalization. However, we also modelled the effect of giving paclitaxel 135 mg m -2 by a 3-h outpatient infusion as is the current practice at the Ottawa Regional Cancer Centre (ORCC). We assumed there was no drug wastage.
Hospitalization for complications occurred in 8.8% of etoposide/cisplatin cycles, compared to 7.4% for paclitaxel/cisplatin and 9.0% for paclitaxel/cisplatin/G-CSF. These hospitalizations were predominantly for haematologic toxicity. We calculated the average cost for such admissions through the Ottawa General Hospital Case Costing System. We obtained physician fees from the most recent Ontario Health Insurance Plan (OHIP) Schedule of Benefits. Because the investigations done in a clinical trial often do not reflect usual practice, we modelled the pretreatment blood work and imaging tests required prior to and during chemotherapy administration on those used in routine care at the ORCC. We determined the cost of these tests from the OHIP Schedule of Benefits. We assumed that test results were not duplicated as patients moved through the health care system.
The amount of time spent by nursing and pharmacy personnel involved in preparing and administering each type of chemotherapy was measured by the staff of the ORCC. We calculated the cost of personnel time by multiplying the amount of professional time expended by the 1997 hourly rates at the ORCC. Finally, nursing staff tracked and costed the actual supplies used in the preparation of paclitaxel. We extracted the 'hotel' costs of clinic visits from the BR 5 study and inflated them to 1997 dollars. We assumed the cost of terminal care hospitalization for patients receiving paclitaxel to be similar to that of patients receiving chemotherapy in the BR 5 study, as determined in the economic analysis of that trial (Jaakkimainen et al, 1990) .
Survival data
We obtained the raw survival data of patients in the ECOG randomized trial (Bonomi et al, 1996 (Bonomi et al, , 1997 from Bristol-Myers Squibb. We incorporated it into our model using a piecewise Weibull function (Figure 1 ) and determined the average survival gain. The Weibull function is a standard, flexible, parametric survival model commonly used by biostatisticians to model failure time data in cancer patients.
The lung cancer costing model
Statistics Canada developed the lung cancer costing model as part of a larger project to simulate the health of Canadians. The POpulation HEalth Model (POHEM) is a software framework that integrates data on risk factors for major diseases, disease onset and outcome, health care utilization and direct care costs. The model generates a hypothetical cohort of people with demographic and labour force characteristics, risk factor exposures and health histories typical of Canadians. The perspective of the costing model is that of a provincial government payer in a universal health care system. We have reported the lung cancer costing submodel previously (Evans et al, 1993 (Evans et al, , 1995a (Evans et al, , 1995b (Evans et al, , 1995c (Evans et al, , 1997a (Evans et al, , 1997b Evans and Chevalier, 1996; Earle and Evans, 1997) . In brief, it assigns individuals to a particular histologic cell type based on the distribution of these characteristics in the Canadian Cancer Registry. Stage distribution is based on retrospective chart reviews. It then assigns diagnostic work-up, treatment, disease progression and survival characteristics based on data from the medical literature, provincial registries and nationwide physician surveys. Finally, it allocates costs to the various components of care appropriate for cell type and stage of disease, from initial diagnosis through to terminal care. We assumed that terminal care costs were similar for patients in the three study arms. The model has recently been updated with 1992 incidence data. All costs are in 1997 Canadian dollars ($1.00 Canadian ~ £0.39 sterling). Because survival is very short for these patients, discounting was not applied.
We integrated the cost and survival data described above into POHEM to carry out our analyses. Cost-effectiveness, expressed as the cost per life-year gained (LYG) was calculated by the formula:
Sensitivity analyses
Because clinical trials often produce efficacy results that are superior to those seen in routine practice, we did sensitivity analyses in which we decreased the survival differences between the regimens by 25 and 50%. A generic version of paclitaxel has recently become available in Canada, resulting in a decrease in price. Therefore, we did sensitivity analyses around the cost of chemotherapy and its administration, increasing it to pre-generic pricing. Because the majority of stage IV lung cancer patients in Canada are still managed without palliative chemotherapy (Raby et al, 1995) , we also compared the survival of paclitaxel/cisplatintreated patients to that of best supportive care (BSC). To do this, we modelled the survival of patients managed by BSC on the NCIC BR 5 trial (Jaakkimainen et al, 1990 ), a three-armed randomized trial comparing BSC to two chemotherapy regimens (Figure 2) . We also did analyses restricted to stage IV patients only, as they did not benefit as much from chemotherapy as stage III patients in the ECOG 5592 trial. Table 1 presents a summary of the direct costs of chemotherapy administration for the different arms assessed in our model. In the ECOG 5592 study, patients in the etoposide/cisplatin arm received a median of four cycles of chemotherapy, as did those in the paclitaxel/cisplatin/G-CSF arm, while those in the paclitaxel/cisplatin arm received a median of five treatment cycles. The total cost of administering a course of paclitaxel (135 mg m -2 )cisplatin was $13 841 when given by 24-h infusion as an inpatient. This fell to $7832 when we modelled it at the same doses as an outpatient 3-h infusion. Paclitaxel, G-CSF and inpatient hospital care were the largest contributors to the cost of treatment.
RESULTS

Principal analysis
The average survival of patients treated with paclitaxel/cisplatin calculated from the combined arms of the ECOG study exceeds that of etoposide/cisplatin by 1.6 months. From these data we were able to calculate that the paclitaxel/cisplatin arm as given in the trial costs $76 370 per LYG, while the paclitaxel/cisplatin/G-CSF regimen costs $138 578 per LYG. However, if the paclitaxel/cisplatin regimen could be given as an outpatient with the same effectiveness, the cost-effectiveness would improve to $30 619 per LYG (Table 2) .
To put these numbers into a national perspective, in 1992 there were 4986 cases of stage IV NSCLC in Canada. The total cost to Table 3 shows the effects of varying selected assumptions in the model. If the survival gain was only 50% of that reported, the costeffectiveness ratio would rise to $71 321 per LYG. Considering only stage IV patients, who had less survival gain in the trial, the cost-effectiveness was still acceptable at $44 756. Using the higher cost of paclitaxel before it became generic, the cost-effectiveness ratio rose to $49 028. In non-randomized comparisons with BSC, paclitaxel/cisplatin cost $4539 per LYG for stage IIIb and IV patients, and $5114 per LYG if the analysis was restricted to stage IV patients.
Sensitivity analysis
DISCUSSION
Our study suggests that the paclitaxel/cisplatin regimen can be a cost-effective improvement in the treatment of advanced lung cancer when given on an outpatient basis. Accepted thresholds for a cost-effective treatment intervention range from $20 000 to $100 000 per quality adjusted life-year (Laupacis et al., 1992) .
Most of our cost estimates fall within these guidelines. High-dose paclitaxel given by 24-h inpatient infusion and supported with G-CSF was clearly not cost-effective when compared with etoposide/cisplatin. As has been observed in other situations (Canadian Coordinating Office for Health Technology Assessment, 1997), this strategy provided no advantage over lower dose treatment, but resulted in more toxicity. However, we found paclitaxel/cisplatin to be cost-effective when we modelled it given as a 3-h outpatient infusion. This assumes that the survival benefit would be similar despite this modification in its administration. Shorter paclitaxel infusions have been reported to be less toxic than longer infusions, with comparable response rates (Hainsworth et al, 1995) . However, a recent randomized trial of 3-versus 24-h paclitaxel infusions in breast cancer found the longer infusion yielded a superior response rate (Mamounas et al, 1998) . With respect to survival, two other randomized trials involving paclitaxel/cisplatin in advanced NSCLC found superior response rates but were unable to demonstrate a survival advantage for this regimen (Gatzemeier et al, 1998; Giaccone et al, 1998) . Neither had standard control arms, so survival may have been similar in each trial because both regimens were superior to standard. However, both of these trials gave paclitaxel by 3-h infusion, raising the possibility that the shorter infusion duration decreased the survival benefit of treatment.
Our sensitivity analysis showed these results to be robust to most assumptions. When compared to best supportive care, the care most often given to advanced lung cancer patients in Canada (Raby et al, 1995) , paclitaxel/cisplatin is a very cost-effective regimen. However, this analysis relied on a non-randomized comparison of survival experiences that may not accurately represent the survival benefit.
We did not directly incorporate quality of life adjustments into our analysis. In the clinical trial there was no significant difference in toxicity in any of the three arms. Furthermore, quality of life measures indicated that quality of life was as good or better in the Numbers may not add due to rounding. paclitaxel-containing arms. As a result, calculation of costs per quality-adjusted life-year would not be expected to be significantly different from the costs per life-year gained in our analyses. If anything, improved quality of life would make paclitaxel/cisplatin more cost-effective. Lung cancer is not an overly expensive disease to treat. However, by virtue of its high incidence it has a significant impact on total health care expenditures. Despite being cost-effective, treating all stage IV NSCLC patients in Canada with paclitaxel and cisplatin as outpatients would cost $155 million, an additional $15 million per annum compared to BSC. However, this is an overestimate because oncologists in Canada are still very conservative towards the treatment of advanced lung cancer, and would not offer treatment to all of their patients (Raby et al, 1995) . In addition, many patients are not candidates for systemic therapy because of age, performance status, or co-morbid conditions. Consequently, the actual impact on health budgets of bringing paclitaxel/cisplatin into routine use is likely to be more modest. As advances in cancer research make more treatments available, society is increasingly asking practitioners to assess the costs and the benefits of the treatments provided. Given these considerations, outpatient paclitaxel/cisplatin chemotherapy can be considered both an effective and a cost-effective treatment for advanced NSCLC that is competitive with many other commonly accepted health care practices (Detsky and Naglie, 1990) .
